Anthropic CEO Predicts AI Will Cure Major Diseases in a Decade
Dario Amodei says AI could drive cures for most major diseases within five to ten years, citing a new gene-editing discovery.
Key points
- Anthropic CEO Dario Amodei predicts AI could help cure most major diseases within the next five to 10 years.
- The company's AI model, Claude, discovered a molecular machine that may represent a new gene-editing mechanism.
- While AI can accelerate discovery, humans must still perform physical experiments and regulatory reviews for new treatments.
Anthropic CEO Dario Amodei predicted on Wednesday that AI could help cure most diseases within the next five to 10 years. He made this claim while discussing a new molecular discovery made by the company's AI model, Claude.
The company announced that Claude identified a molecular machine that may represent a new gene-editing mechanism. Amodei stated that this finding shows AI is becoming a powerful tool for biological research.
Claude identifies new biological mechanism
According to Anthropic, the AI system read through scientific literature and genome data to find the discovery. The team then proposed experiments to verify the finding, which they carried out successfully.
However, the company admits the precise biological function of this machine remains unclear. Amodei noted that the biotechnological utility of the discovery is not yet known, calling it a significant but unproven result.
AI performance improves rapidly in science
Amodei pointed to a pattern where AI moves from weak to superhuman in new fields quickly. He cited math as an example, noting that models struggled in 2023 but are now solving top open problems.
He believes biology is following a similar exponential trend. While math can be solved theoretically, biology requires physical experimentation, which creates a different set of challenges for AI systems.
Human collaboration remains essential for testing
Amodei emphasized that humans must currently carry out the physical experiments. He said AI can help validate results in weeks, but it cannot yet safely control lab equipment autonomously.
This process will not shorten clinical trials, but it may produce more promising drug candidates. Any resulting treatments will still require standard regulatory review before they can be used by the public.
Fox Business reported that Amodei also spoke before the U.N. Security Council earlier in the week. He urged the industry to establish international standards to manage the threats posed by rapid AI developments.
